Eurolac

Short-term management of moderate post-op pain.

10 mg every 4-6 hr. Doses >40 mg/day are not recommended. Patient receiving ketorolac amp & converted to ketorolac tab Total combined daily dose should not exceed 90 mg (60 mg for elderly, renally-impaired patient & patient <50 kg). Elderly Longer dosing interval (eg, 6-8 hr) is advisable.

Should be taken with food: Take immediately after meals.

Hypersensitivity to ketorolac trometamol or to other NSAIDs. Patients in whom aspirin or other prostaglandin synthesis inhibitors induce allergic reactions. History of peptic ulcer or GI bleeding; suspected or confirmed cerebrovascular bleeding; hemorrhagic diatheses including coagulation disorders; complete or partial syndrome of nasal polyps, angio-edema or bronchospasm; hypovolemia or dehydration; history of asthma. Patients who have had operations w/ a high risk of hemorrhage or incomplete hemostasis. Patients on anticoagulants including low-dose heparin (2,500-5,000 u 12-hrly). Concurrent treatment w/ other NSAIDs, oxpentifylline, probenecid or lithium salts. Moderate or severe renal impairment (serum creatinine >160 micromol/L). Pregnancy, labor, delivery, or lactation. Childn <16 yr.

Discontinue use if signs & symptoms of liver dysfunction or abnormal liver test occur. Risk of bleeding. Risk for serious GI toxicity eg, bleeding, ulceration & perforation. Closely monitor for signs of serious GI adverse events. Not recommended for use beyond 7 days & for chronic use. Not for epidural or spinal administration. Elderly. Patients <50 kg.

Abdominal discomfort, constipation, diarrhea, dyspepsia, eructation, flatulence, fullness, gastritis, GI bleeding & pain, nausea, pancreatitis, peptic ulcer, perforation, stomatitis, vomiting; abnormal dreams, abnormal taste & vision, abnormal thinking, aseptic meningitis, convulsions, depression, dizziness, drowsiness, dry mouth, euphoria, excessive thirst, functional disorders, hallucinations, headache, hearing loss, hyperkinesia, inability to concentrate, insomnia, myalgia, nervousness, paresthesia, stimulation, sweating, tinnitus, vertigo; acute renal failure, flank pain (w/ or w/o hematuria), glomerular nephritis, hemolytic uremic syndrome, hyperkalemia, hyponatremia, increased urinary frequency, interstitial nephritis, nephrotic syndrome, oliguria, raised serum urea & creatinine, renal papillary necrosis; bradycardia, flushing, HTN, pallor, purpura, thrombocytopenia; asthma, dyspnea, pulmonary edema; exfoliative dermatitis, Lyell's syndrome, maculopapular rash, pruritus, SJS, urticaria; anaphylaxis, bronchospasm, flushing & rash, hypotension, laryngeal edema; epistaxis, hematomata, post-op wound hemorrhage; abnormal LFTs, asthenia, edema, inj site pain, wt gain.

Increased plasma level & t_1/2 w/ probenecid. Increased tendency to bleeding w/ oxpentifylline. Possible inhibition of renal clearance, increased plasma conc, & potential toxicity of lithium. Potential additive side effects w/ other NSAIDs. Increased risk of renal impairment w/ ACE inhibitors, particularly in vol-depleted patients. Reduced diuretic response to furosemide. May reduce clearance & enhance toxicity of MTX.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AB15 - ketorolac ; Belongs to the class of acetic acid derivatives and related substances of non-steroidal antiinflammatory and antirheumatic products.

Rx